The Cannabis Production Landscape in the United Kingdom ICC is well positioned to support increased medical cannabis demands in the UK. The history of cannabis production in the United Kingdom Many of Britain’s colonies prohibited the use of cannabis early on. Prohibited in 1928, recreational cannabis in the United Kingdom (UK) is considered a Class B drug. It was lowered in 2004 to a Class C but was reinstated as Class B as recently as 2009. Recreational cannabis production and distribution is considered criminal. November 2018 finally saw the legalization of medical cannabis in the UK, including Wales and Scotland. The irony being that as of 2016, the UK was the world’s largest distributor of legal cannabis in the form of Sativex and Epidiolex, used to relieve the symptoms of MS and Epilepsy respectively. Legalization of medical cannabis in the UK was supported and accelerated by the expertise of Dr. Michael Barnes MD FRCP, neurologist and medical cannabis physician. Dr. Michael Barnes MD FRCP was consulted throughout the legalization process for his extensive knowledge on medical cannabis policies in Europe. The legislation allows for the prescription of cannabis from a medical professional, via a regular pharmacy access model, and is covered under National Health Service Insurance.
Opportunities for Medical Marijuana Processing and Distribution in the United Kingdom The United Kingdom has a population of 65.6 million people, with healthcare expenditures topping out at 221.7 billion Euros. The UK population is growing quickly, projected to reach 74 million by 2040. 18% of the UK population is aged 65 and older. Advocacy group, End Our Pain, estimates that one million people require access to medical cannabis in the UK. With the current domestic grow operations focused on export, the UK residents have had to take a back seat, a situation that International Cannabis Corp. is working to quickly correct.
International Cannabis Corp’s role in cannabis production and distribution in the UK With the support of Dr. Michael Barnes MD FRCP, Theros Pharma Ltd., a holding of International Cannabis Corp. (ICC) and an early stage company, is successfully distributing cannabis to the UK for patients who have a prescription. Theros Pharma Ltd. is one of eleven ICC holdings in Europe and further expands ICC’s European network for medical marijuana processing and distribution.
What is next for Cannabis in the UK?
CBD oil is considered legal in the UK if it carries authorized product licensing. CBD oil usage is one of the UK’s fastest growing industries, doubling its users from 125,000 in 2017 to 250,000 in 2018. ICC is poised to be a leading producer and supplier of CBD into the UK as import relations grow. ICC with Wayland Group have introduced extraction, distillation processes and finished dose manufacturing into their CBD product plan for the European market. By following the method of Hydrocarbon extraction, ICC can ensure the highest standard of CBD product. ICC has holdings in Germany, Poland, Portugal, Greece, Italy, Malta, Macedonia, and Bulgaria with the goal of increasing CBD production ten-fold in those countries, and to distribute to 160 clients in over 16 European countries. The United Kingdom could easily benefit from ICC’s knowledge, calibre of strains, and ability to produce the highest quality of cannabis products. The UK’s stiff upper lip is sure to soften, as its policy makers, medical professionals and communities become more knowledgeable to the medical benefits of medical marijuana. Now that medical cannabis is legal for distribution in the UK the proof will certainly be in the pudding. Visit!
https://intlcannabiscorp.com/